The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000478314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
23/03/2026
Date registered
Help: Date registered
17/04/2026
Date last updated
Help: Date last updated
17/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Feasibility of an Exercise Prehabilitation Program for adults with lymphoma planned to receive Chimeric Antigen Receptor (CAR) T-cell therapy (CAR-T Therapy)
Scientific title
Feasibility of an Exercise Prehabilitation Program for adults with lymphoma planned to receive CAR-T Therapy – The Fit4CAR-T Trial
Additional trial identifiers [1] 316817 0
Nil
Universal Trial Number (UTN)
U1111-1337-6249
Trial acronym
The Fit4CAR-T Trial
Related trial records
N/A

Health condition
Health condition(s) studied:
Haematological Cancer 341185 0
Lymphoma 341186 0
Lymphoma (non Hodgkin's lymphoma) 341424 0
Condition category
Condition code
Cancer 337271 337271 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The exercise intervention will consist of an individualised, supervised structured exercise program combining aerobic and resistance exercises delivered through telehealth in the 4 weeks directly prior to starting Chimeric antigen receptor (CAR) T-cell therapy.

Exercise Program
Participants will be provided with an individualised training program that they will carry out in supervised telehealth sessions at the participant’s home using the telehealth application, Physitrack. This application allows for the exercise session to be monitored (including exercise intensity) and instructed online, using mobile devices. The participants will download the application free of charge on their own devices, supported by research staff. The application will not collect any personal information and will only provide the participant with example exercise prescription videos and will be used to monitor participant’s adherence to the study exercise program. Only researchers involved in the study will have access to this exercise adherence information. Participant’s accounts and all information stored in the application will be deleted from the server at the completion of the study as adherence data will be recorded in Research Electronic Data Captue (REDcap) like all other outcome variables. The participants study account will be deleted. Telehealth-based exercise interventions are used routinely, and good adherence has been demonstrated previously by the research team. Any necessary equipment to perform these sessions will be provided for the participants. The exercise physiologist will prescribe and supervise three 30-45 minute sessions of structured exercise per week for 4 weeks. These sessions will include an aerobic (goal 20 minutes per session) and a resistance (goal 10-15 minutes per session) exercise component as well as brief warm-up and cool-down periods (5 minutes each).

For the aerobic component, participants will alternate between:
Continuous aerobic exercise at a constant intensity (60% maximum capacity or rate of RPE of 12-14) or Interval training (4 x 2 minutes of interval bouts at ~80% of maximal capacity or rate of perceived exertion (RPE) of 16+ separated by 3 minutes of active recovery). Aerobic activities will include step up and on the spot activities, as well as walking outside.

The exercise workload corresponding to the required intensity will be individualised for each participant based on their performance in the baseline cardiopulmonary exercise test (CPET). Considering the characteristic undulating health and fatigue status of these patients, participants will be asked to continually rate their RPE throughout the exercise. The RPE scale will provide a measure of the participant’s relative intensity so that we can alter the intensity as necessary. No equipment will be required for this component of the exercise session.

The supervised resistance exercise component will comprise simple progressive body-weight and stretch resistance band activities, consisting of 4-6 exercises targeting major muscle groups in the legs, chest, shoulders, arms and core (for example- standing squat, split lunge, chest press, standing row). Participants will be provided with these resistance bands at no cost at the conclusion of the initial testing session. They will not be required to return them at the conclusion of the study. Should they become damaged, study researchers will send them a new one directly at no cost to the participant. Participants will work towards performing 2 sets of each exercise with a goal of 10-12 repetitions at an RPE of 14-16. Once the participants can complete 12 repetitions at an RPE of 13, the intensity will be increased using therabands (stretch resistance bands). Adherence to the exercise prescription will be documented by the physiotherapist or exercise physiologist (who will supervise all sessions), including total exercise duration, RPE and heart rate. Participants will not be offered the exercise intervention following the conclusion of the study.
Intervention code [1] 333513 0
Lifestyle
Intervention code [2] 333549 0
Prevention
Intervention code [3] 333696 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344785 0
Recruitment rate
Timepoint [1] 344785 0
Upon conclusion of the study recruitment
Primary outcome [2] 344786 0
Completion rate
Timepoint [2] 344786 0
Upon conclusion of the final participant's final testing session
Primary outcome [3] 344787 0
Attendance
Timepoint [3] 344787 0
Upon conclusion of the final participant's final exercise session
Secondary outcome [1] 459198 0
Adherence to the exercise program- this is an additional primary outcome
Timepoint [1] 459198 0
Upon conclusion the final participant's final exercise session
Secondary outcome [2] 459199 0
Program tolerance- resistance training- this is an additional primary outcome
Timepoint [2] 459199 0
Upon conclusion of the final participant's final exercise session
Secondary outcome [3] 459200 0
Safety- this is an additional primary outcome
Timepoint [3] 459200 0
Assessed at each exercise session over the 4 week intervention period
Secondary outcome [4] 459201 0
Acceptability
Timepoint [4] 459201 0
Assessed within 2 weeks following the participant's final testing session.
Secondary outcome [5] 459202 0
Peak oxygen uptake
Timepoint [5] 459202 0
Assessed at baseline (week directly prior to beginning the exercise intervention) and directly post-intervention (the week directly after the completion of the 4 week exercise intervention)
Secondary outcome [6] 459203 0
Frailty
Timepoint [6] 459203 0
Assessed at baseline (week directly prior to beginning the exercise intervention) and directly post-intervention (the week directly after the completion of the 4 week exercise intervention)
Secondary outcome [7] 459204 0
Lower body muscle strength
Timepoint [7] 459204 0
Assessed at baseline (week directly prior to beginning the exercise intervention) and directly post-intervention (the week directly after the completion of the 4 week exercise intervention)
Secondary outcome [8] 459205 0
Exercise self-efficacy
Timepoint [8] 459205 0
Assessed at baseline (week directly prior to beginning the exercise intervention) and directly post-intervention (the week directly after the completion of the 4 week exercise intervention)
Secondary outcome [9] 460051 0
Program tolerance- resistance training- this is an additional primary outcome
Timepoint [9] 460051 0
Upon conclusion of the final participant's final exercise session

Eligibility
Key inclusion criteria
1) Greater than or equal to 18 years, male or female
2) Scheduled to receive CAR-T cell therapy for lymphoma cancer
3) ECOG Performance status scale of 0-1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Any health conditions that are contraindicated to the exercise and testing included in the study
2) Unable to speak or understand English
3) Pregnant or planning to become pregnant

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Feasibility and acceptability outcomes will be presented as descriptive statistics. Quantitative variables will be analysed using ANOVAs

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29278 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 45589 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 321411 0
Commercial sector/Industry
Name [1] 321411 0
Gilead Sciences, Inc
Country [1] 321411 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Baker Heart and Diabetes Institute
Address
Country
Australia
Secondary sponsor category [1] 324190 0
None
Name [1] 324190 0
Address [1] 324190 0
Country [1] 324190 0
Other collaborator category [1] 283882 0
Hospital
Name [1] 283882 0
Bayside Health/Alfred Hospital
Address [1] 283882 0
Country [1] 283882 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319950 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 319950 0
Ethics committee country [1] 319950 0
Australia
Date submitted for ethics approval [1] 319950 0
24/11/2025
Approval date [1] 319950 0
03/12/2025
Ethics approval number [1] 319950 0
714/25

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148930 0
A/Prof Erin Howden
Address 148930 0
Baker Heart and Diabetes Institute, 99 Commercial Road, Melbourne, VIC, Australia 3004
Country 148930 0
Australia
Phone 148930 0
+61436112343
Fax 148930 0
Email 148930 0
Contact person for public queries
Name 148931 0
Erin Howden
Address 148931 0
Baker Heart and Diabetes Institute, 99 Commercial Road, Melbourne, VIC, Australia 3004
Country 148931 0
Australia
Phone 148931 0
+61436112343
Fax 148931 0
Email 148931 0
Contact person for scientific queries
Name 148932 0
Erin Howden
Address 148932 0
Baker Heart and Diabetes Institute, 99 Commercial Road, Melbourne, VIC, Australia 3004
Country 148932 0
Australia
Phone 148932 0
+61 436112343
Fax 148932 0
Email 148932 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• Published results
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.